Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592801 | 0.83 | LMNA (0.39) | MAPTALDH1A1KMT2ALMNAPKM | |
| SCHEMBL6592795 | 0.76 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL2576999 | 0.75 | ALDH1A1 (0.55) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL6596250 | 0.73 | ALDH1A1 (0.48) | MAPTALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL3073603 | 0.72 | TDP1 (0.44) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3087284 | 0.72 | MAPT (0.44) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3073601 | 0.72 | TDP1 (0.44) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3087288 | 0.72 | MAPT (0.44) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3085773 | 0.72 | MAPT (0.43) | MAPTALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3085774 | 0.72 | MAPT (0.43) | MAPTALDH1A1KMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189883-B1 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6548533-B2 | Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-04-15 | — | — | US | disclosed |
| US-20020094994-A1 | Substituted pyrrolidines | AVENTIS PHARMA LIMITED (GB) | 2002-07-18 | — | — | US | disclosed |
| EP-1189883-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | Aventis Pharma Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000068195-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094994-A1 | Substituted pyrrolidines | VCAM1, ITGB1, ITGA1 | MAPT 4820/4885ALDH1A1 438/4885KMT2A 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.